The 2024 European Society for Medical Oncology (ESMO) Annual Congress will take place from September 13th to 17th in Barcelona, Spain. As an annual celebration in the field of oncology, ESMO attracts tens of thousands of oncology experts from around the world every year, providing a great platform for global scholars to exchange ideas. Currently, the official ESMO website has published the titles of the selected studies. This issue specially compiles the key research in the field of hematological malignancies (Mini oral) for everyone to refer to in advance.01 Abstract Number：799MO
The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
02 Abstract Number：800MO
First Report of BCL-2 Inhibitor TQB3909 in Pts with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML): Data From a Phase 1 Study
03 Abstract Number：801MO
Efficacy and Safety of a Phase 2 Study: Timdarpacept (IMM01) Combined with Azacitidine (AZA) As the First-Line Treatment in Adults with Chronic Myelomonocytic Leukemia (CMML)
04 Abstract Number：802MO
Real-world Comparison of Overall Survival between BCMA – Bispecific and CAR-T Therapies in Multiple Myeloma
05 Abstract Number：803MO
CAR-T cells reside in the bone marrow and inhibits healthy hematopoiesis
06 Abstract Number：804MO
Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity
07 Abstract Number：805MO
Real-world efficacy and safety of Tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the Early Access Program through the French DESCAR-T registry
08 Abstract Number：806MO
Phase 1b study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
09 Abstract Number：807MO
High Efficacy and Safety of Interleukin-6-knockdown CD19-targeted CAR T cells in relapsed/refractory B-ALL patients
10 Abstract Number：808MO
Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy
11 Abstract Number：809MO
Efficacy and safety results from the phase 2 study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
12 Abstract Number：810MO
Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A phase l/II Study
13 Abstract Number：811MO
An Exploratory Study to Assess the Safety, Immunogenicity, and Preliminary Anti-tumor Activity of the EBV mRNA vaccine (WGc-043 injection) in Patients with NK/T Cell Lymphoma
14 Abstract Number：812MO
Initial Results of the Multicenter Phase 2 Trial of a Novel Hypofractionated Low-dose Radiotherapy for Indolent non-Hodgkin Lymphoma
15 Abstract Number：813MO
Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients
16 Abstract Number：814MO
Molecular Biology Study of Primary Immuno-privileged Lymphomas
17 Abstract Number：815MO
A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): preliminary analysis on efficacy and safety
18 Abstract Number：816MO
Two Hematological Precursors and Their Impact on Hematological Malignancies
